March 12, 2025

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

Scrip Code: **530019**

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 051

Symbol: **JUBLPHARMA**

Dear Sirs,

In continuation to our letter dated January 16, 2025 and in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that the Company's subsidiary **Jubilant Cadista Pharmaceuticals Inc., USA, (Jubilant Cadista)'s** solid oral formulations facility at Salisbury, Maryland, USA (**Facility**) has received the Establishment Inspection Report (**EIR**) with **Voluntary Action Indicated (VAI)** status from the US Food and Drug Administration (**USFDA**) for the said Facility with respect to the inspection conducted by the said regulatory agency in January 2025.

With the receipt of the EIR from the USFDA, the inspection stands successfully closed.

Going forward, the said Facility is not expected to manufacture any products as it has closed manufacturing operations, as was informed in Company's previous disclosure dated April 18, 2024.

Jubilant Cadista has received communication from USFDA at 09:27 pm (IST) on Tuesday, March 11, 2025.

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited
Naresh Kapoor
Digitally signed by Naresh Kapoor
Date: 2025.03.12 18:31:47 +05'30'
Naresh Kapoor
Company Secretary

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624